NCT06321523 - A Study to Learn About the Study Medicine Called Tafamidis 61mg in People Diagnosed With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 19, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions

Transthyretin Amyloid Cardiomyopathy

Interventions

DRUG

Tafamidis 61 milligrams

Tafamidis 61mg as provided in real-world practice

Trial Locations (3)

ACTIVE_NOT_RECRUITING

Pusan National University Hospital, Busan

ACTIVE_NOT_RECRUITING

Severance Hopital, Yonsei University Health System, Seoul

RECRUITING

Gangnam Severance Hospital, Seoul